ABSTRACT
INTRODUCTION
Esophageal cancer is an aggressive gastrointestinal malignancy with a poor prognosis. 1 It is diagnosed in about 400,000 patients each year worldwide, and its incidence is increasing. 2 Due to the lack of widespread screening methods, its insidious symptomatology, a late clinical presentation, and rapid progression, diagnosis is usually made at advanced stages. 1, 3 Therefore the 5-year survival rate of patients with esophageal cancer is less than 20%. Most patients already present with locally advanced, unresectable or metastatic disease and only suitable for palliative therapy. 3 The predominant symptom of advanced esophageal cancer is dysphagia with 80-90% of all 1 It is one of the most distressing and debilitating symptoms in patients with cancer-related esophageal obstruction. Dysphagia leads to nutritional compromise, pain, and deterioration of quality of life. 3 As the quality of life, and to some extent the quantity of life remaining to these patients depends to a large degree on their ability to swallow, the relief of dysphagia is therefore a priority for any palliative treatment of patients suffering from esophageal cancer. 1, 3 Several treatment modalities are used for the palliative care of dysphagia in patients with inoperable esophageal cancer, including radiotherapy (endoluminal and external-beam), endoscopic ablation (for example, by laser, cryotherapy, photodynamic therapy), endoluminal plastic and metallic stents, and resection or bypass surgery. Of those approaches, endoluminal stenting and radiation therapy are the ones most commonly used. 4 In the past there have been attempts to combine radiotherapy with stent placement in patients with esophageal cancer. These efforts are based on the premise that radiotherapy and stenting complement each other. Stents provide rapid relief of dysphagia and maintain nutrition during radiotherapy. Radiotherapy, in turn, provides lasting dysphagia relief by retarding tumor growth and, possibly, improves survival. 1 This paper was aimed to evaluate the comparison of palliative treatment using esophageal stenting alone or in combination with radiotherapy.
CLINICAL QUESTION
A 48 year-old man came with the chief complain of black stool since 2 days before admission. The history throat or fever were denied. He was still able to eat solid food, but gradually he can only consume liquid food or just drink milk. This patient already went to other hospital and underwent esophagogastroduodenoscopy (EGD). The doctor said that there was a tumor in his esophagus, but the biopsy results were never conclusive although it has been done for seven times. The deployment of esophageal stent has been carried out in this patient at that time because there was already constricture at his esophagus. At 2 days before the three times a day in small quantities. It also became of appetite but nausea and vomiting were denied. He also suffered from weight loss, approximately 10 kg in the last 3 months. Any other symptoms were denied. He has no history of chronic diseases such as diabetes mellitus, hypertension, heart disease, kidney disease, pulmonary disease, asthma, or allergies. He also did not admit for alcohol consumption or smoking. There is no history of similar disease or other chronic disease such as malignancy in the family.
From a complete physical examination, stable hemodynamic was found. Abdominal examination showed palpable liver approximately 2 cm below processus xyphoideus. On rectal touché, black stool were found. No other abnormalities were found. From the laboratory examination at emergency ward, we found normocytic normochrome anemia (Hb 8.43 Yaldiera Utami, Achmad Fauzi leukocytosis (Leu 10.600/uL). Electrolytes were normal (Sodium 137/Potassium 4.0/Chloride 104 mEq/L) and also no elevation of transaminases (AST 20/ALT 10 u/L) nor ureum/creatinine level (21.5/1.0 mg/dL). Later on we also checked on the fecal occult blood test and the result was positive. Serologic markers for hepatitis B, C, and HIV infections showed negative result. The level of LDH was slightly increased (331 u/L) and AFP level was normal (0.9 IU/mL). Hemostasis were normal with no prolonged PT nor aPTT. Chest X-Ray and electrocardiography showed no abnormalities.
Before the admission, this patient already underwent several examination at other hospital. Chest CT-scan showed esophagogastric tumor with stent deployed suspect malignancy and no abnormalities in the heart and lung. Esophagogastroduodenoscopy showed esophageal tumor with stent deployed and covered by tumor growth. The biopsy result showed reflux esophagitis with ulceration. OMD showed irregularity at gastroesophageal junction with stent deployed and narrowing lumen. Abdominal ultrasound of the liver. Abdominal CT-scan showed solid tumor at distal esophageal spread through cardia and fundus coeliacus truncus lymphadenopathy.
Based on anamnesis, physical examination, laboratory and other supports, we conclude the list of problems in this patient are: (1) melena et cause GI bleeding dd/ tumor bleeding; (2) esophageal tumor et cause suspected malignancy with tumor bleeding and metastasis to the liver; (3) normocytic normochrome anemia et cause tumor bleeding dd/ anemia of chronic disorder. The patient was treated using the nasogastric tube to evaluate the bleeding and was started to be given liquid food 1700 kkal per day as soon as the bleeding stopped. Other treatment were intravenous Normal saline and Triofusin 500 mL, PPI 2 x 40 mg iv, Sucralfate 3x15 mL po, Vitamin K 3x10 mg iv, Transamin 3x500 mg iv, Lactulax 3x15 ml, Curcuma 3x200 mg, and PRC transfusion with targeted Hb 10 mg/dL.
During the treatment at our hospital, this patient underwent another EGD procedure and biopsy of the squamous cell carcinoma spread to the stomach and also liver metastases. While deciding the next step of patient is getting more serious. Sometimes he said that he is not even able to swallow liquid food. Apparently the use of esophageal stent may not be as effective as expected.
Does a combination of esophageal stent and radiotherapy give the best outcome for the relief of dysphagia in patients with inoperable esophageal carcinoma compare to esophageal stenting alone? We conduct a searching in PubMed site by using three keywords; they are "inoperable esophageal carcinoma" AND "esophageal stent" AND "radiotherapy" on June . Based on this search strategy, we found 32 articles matched the keywords. From these 32 articles, only 10 articles were published in the last 5 years. Thus, from the searching step, there were 10 articles that go to the next process. The next process was selection by reading all articles (10 articles). The articles which were included in this EBCR consist of study which compare combination of esophageal stent and radiotherapy directly with esophageal stent alone. There were 9 articles excluded from analysis because it did not showed the selection process for the most relevant clinical evidence in this EBCR:
METHOD
Palliative Stenting With or Without Radiotherapy for Inoperable Esophageal Carcinoma We finally choose one randomized trial study written by Javed A, Pal S, Dash NR, Ahuja V, Mohanti BK, Vishnubhatla S, et al goes to the critical appraisal step. In appraising the scientific evidence of the article, we use the guidance of critical appraisal of a randomized controlled trial written by Guyatt et al in Critical Appraisal Skills Programme. Details of the article is described in the following table: 
RESULTS
In this EBCR, one prospective, randomized study is collected and compares directly the duration of relief of dysphagia in patients with inoperable esophageal cancer treated with esophageal stenting alone (group I) or a combination of esophageal stenting and radiotherapy (group II), and to assess overall survival, treatment-related complications, and quality of life (QOL) of the patients.
The result of this study showed that dysphagia both groups following stent insertion. The scores were assessed at baseline (before the start of therapy), 1 week after esophageal stenting, 1 week after completion of radiotherapy (in group II), and every 2 months there after until death or until completion of the study. However, dysphagia relief was more sustained in group II than in group I (7 vs. 3 months, p = 0.002). Overall median survival was higher in group II than in group I (180 vs. 120 days, p = 0.009). Addition of radiotherapy following stenting prolonged the mean dysphagia-free survival (118.6 ± 55.8 vs. 96.8 ± 43.0 days, p = 0.054). Mean no or minimal dysphagia (dysphagia grade 0-1). There in all QOL parameters at 1 week after stenting. The QOL, declined immediately after radiotherapy. There was no treatment-related mortality, and the incidence of complications was similar in the two groups.
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DISCUSSION
cancer of the esophagus. About 10% of this cancer occur in the upper third of the esophagus (cervical esophagus), 35% in the middle third, and 55% in the lower third. Squamous cell carcinoma and adenocarcinoma account for more than 90% of cases. 1, 5, 6 A variety of causative factors have been implicated in the development of the disease. The etiology of squamous cell esophageal cancer is related to excess alcohol consumption and/ or cigarette smoking. The relative risk increases with the amount of tobacco smoked or alcohol consumed, with these factors acting synergistically. 6 Due to the lack of widespread screening methods, its insidious symptomatology, a late clinical presentation, and rapid progression, diagnosis is usually made at advanced stages. 1, 3 Progressive dysphagia and weight loss of short duration are the initial symptoms in the vast majority of patients. By the time these symptoms develop, the disease is usually incurable, occur until > 60% of the esophageal circumference is with cancer. 6 Dysphagia or obstruction of the passage of food through the mouth, pharynx, or esophagus. It may be associated with pain on swallowing (odynophagia), pain radiating to the chest and/or back, regurgitation or vomiting, and aspiration pneumonia. 6 The obstruction of the esophagus by the tumor causes progres sive solid food dysphagia, often accompanied by weight loss. Weight loss > 10% body mass (at presentation) is an independent indicator of a poor prognosis. This usually occurs once the esophageal lumen diameter is less than 13 mm, which indicates advanced disease. The following table shows grades of dysphagia: 7 Dysphagia from inoperable esophageal cancer is a common and complex management problem, and there is no consensus on the ideal treatment approach. 4 The stage of neoplastic disease, general patient condition and (in consequence) life expectancy, should be taken into ac count in choosing a method for palliative treatment of dyspha gia caused by esophageal cancer. 8 Several treatment modalities are 3. Was the assignment of patients to treatments randomised? 4. Were all the patients who entered the trial properly accounted for at its conclusion? was follow-up complete? were patients analysed in the groups to which they were randomised?
Detailed questions
5. Were patients, health workers and study personnel 'blind' to treatment?
patients? health workers? study personnel?
6. Were the groups similar at the start of the trial? In terms of all the factors that might be relevant to the outcome: age, sex, social class, life style etc.
7. Aside from the experimental intervention, were the groups treated equally?
Is it worth continuing? Yes 8. How large was the treatment effect? What outcomes are measured? Take a note of the result(s) (eg odds ratio, number needed to treat) if provided.
The overall survival, treatment-related complication, and quality of life (QOL)
Results: group receiving combined modalities (p = 0.009). Treatment-related complication was similar in both groups. immediately after radiotherapy. 8. How large was the treatment effect?
What outcomes are measured? Take a note of the result(s) (eg odds ratio, number needed to treat) if provided. The overall survival, treatment-related complication, and quality of life (QOL) Results: receiving combined modalities (p = 0.009). Treatment-related complication was similar in both groups. radiotherapy.
9 11. Were all important outcomes considered? If not, does this effect the conclusion(s)?
12. Is any information provided which could help you decide whether the 13. Accept for further use as Type II evidence in the Protocol Enhancement Project?
used for the palliative care of dysphagia in patients with inoperable esophageal cancer, including radiotherapy (endoluminal and external-beam), endoscopic ablation (for example, by laser, cryotherapy, photodynamic therapy), endoluminal plastic and metallic stents, and resection or bypass surgery. Esophageal intubation for palliation has been used longer than 100 years. Symmonds in 1885 described since then several types of endoprosthesis have been tried. Stenting has proved to be a convenient and long lasting method of palliation for malignant dysphagia. Use of covered self expandable metallic stents (SEMS) and more recently self expandable plastic stents (SEPS) has led to an increase in the success rate in palliative management of strictures of esophagus. 8, 9, 10 Since 1990, several case series, retrospective reviews, and prospective studies including more than 2,000 patients have shown that self-expandable metal stents (SEMS) are effective in relieving dysphagia and improving dysphagia scores, with immediate success rates between 96% and 100%. SEMS provide a substantial progress in the management of patients with inoperable carcinoma esophagus. It is made up of an alloy, usually nitinol or stainless steel is deployed using restores oral intake and reduces hospital stay and cost. 10 However its use is limited by the cost, high rate of recurrent dysphagia, frequent need of re-interventions and several complications. 1, 4, 8, 9 Complications associated with esophageal stents Early complications occur immediately or within 2-4 weeks postprocedure and include chest pain, fever, bleeding, gastroesophageal reflux disease, globus sensation, perforation, and stent migration. In one study, early complications were reported in up to 32% of patients, with stent migration being the most common complaint. Delayed complications are more common than early ones and occur at least 2-4 weeks after placement of a stent. These complications include tumor ingrowth, stent migration, stent occlusion, strictures. Delayed complications have been reported in 53-65% of patients, with a reintervention rate of up to 50%. Among both early and delayed complications, stent migration is the most common complication, occurring at a frequency of 7-75%. 8, 9 Recurrent dysphagia was caused by tumor ingrowth (22%), bolus obstruction (21%), stent migration (9%), 8 This issue has led to the frequent need of re-intervention of the stent. Tumour ingrowth suggested that the longer the stent is in place the more tissue growth will be seen; hence, the longer time with the stent in situ, the more frequent the complications. APC was therefore the most frequent reintervention modality in our study. In some instances, placing a second stent could have been an option, but when the stented area is lengthened, the motility is also reduced. Stent dislocation was another frequent problem. Due to the problems with tumour/tissue ingrowth, covered stents are generally preferred, but it is also known that they tend to migrate more often. To avoid migration, the use of larger diameter stents seems tempting, but studies have shown that these may cause even more complications. The survival after SEMS placement was quite short (mean 116 days) which emphazises the need for quick relief of dysphagia rather than a more prolonged effect.
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Radiotherapy, on the other hand, provides effective and long-term relief of dysphagia. However, the onset of its effect is slow and required up to 6 weeks for edema can actually worsen dysphagia during the early period. Stents placed before radiotherapy prevented this initial worsening of dysphagia. Patients who receive radiotherapy had a more sustained relief of dysphagia, which may have resulted from the inhibition of local tumor by radiotherapy, thereby delaying tumor overgrowth and ingrowth and keeping the stent patent for a longer duration. Besides the better relief of dysphagia, sustained improvement in nutritional status of patients who had received combination therapy might have also contributed to the improved survival in this group. 1 Since then, a few studies have reported superior results for stenting followed by radiotherapy with regard to both relief of dysphagia and survival in patients with inoperable esophageal cancer. 1 A study by Yu et al showed that radiotherapy for esophageal cancer after esophageal stents placement is very helpful in treatment of advanced esophageal cancer. The stent inserted expanded the stenosis site and made it possible for brachytherapeutic treatment and radioactive source to pass easily and eventually dramatically prolonged the patients' survival period. 12 The dose of radiotherapy used in combination with stenting also need to be considered properly. Most studies have used radiotherapy in a dose range of 40-60 Gy. However, a higher dose of radiotherapy does not add to the
